Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark
California
94560
United States
Tel: 650-587-5766
Fax: n./a
Website: http://www.protagonist-inc.com/
Email: info@protagonist-inc.com
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.
YEAR FOUNDED:
2001
LEADERSHIP:
Founder: Mark Symythe
CEO: Dinesh Patel
CMO (Marketing): Richard Shames
CFO: Tom O’Neil
CSO (Scientific): David Liu
JOBS:
Please click here for Protagonist Therapeutics job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
211 articles about Protagonist Therapeutics, Inc.
-
Protagonist Therapeutics Initiates Phase 1 Study With Oral Peptide PTG-100
1/8/2016
-
Protagonist Therapeutics Receives SBIR Funding For Oral IL-23 Receptor Antagonists For Treatment Of Inflammatory Bowel Diseases
9/24/2015
-
Protagonist Therapeutics Names Richard S. Shames, M.D. As Chief Medical Officer
9/10/2015
-
Bay Area's Protagonist Therapeutics Fetches $40 Million to Bring Next-Gen IBD Drugs to Trial
7/16/2015
-
Protagonist Therapeutics Names William A. Hodder As Senior Vice President, Corporate Development
12/18/2014
-
Protagonist Therapeutics Closes 2nd Tranche Of $18 Million Series B For Advancing Development Candidate To Clinical Trials In 2015
12/4/2014
-
Protagonist Therapeutics Expands Series B Financing to $18 Million With Addition of $4 Million From Pharmstandard
9/19/2013
-
Protagonist Therapeutics Pulls in $14 Million, Led by Johnson & Johnson, for Peptide Pills
6/4/2013
-
Protagonist Therapeutics Names David Liu Chief Scientific Officer
5/30/2013
-
Protagonist Therapeutics and Ironwood Pharmaceuticals Expand Peptide Drug Discovery Collaboration
12/6/2012
-
Zealand Pharma and Protagonist Therapeutics Team Up for Peptide Drug Discovery and Development
6/18/2012